Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

789 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
Dieci MV, Prat A, Tagliafico E, Paré L, Ficarra G, Bisagni G, Piacentini F, Generali DG, Conte P, Guarneri V. Dieci MV, et al. Among authors: conte p. Ann Oncol. 2016 Oct;27(10):1867-73. doi: 10.1093/annonc/mdw262. Epub 2016 Aug 2. Ann Oncol. 2016. PMID: 27484801 Free article. Clinical Trial.
New combinations with epirubicin in advanced breast cancer.
Conte P, Gennari A, Landucci E, Guarneri V, Donati S, Salvadori B, Bengala C, Orlandini C. Conte P, et al. Oncology (Williston Park). 2001 May;15(5 Suppl 7):24-7. Oncology (Williston Park). 2001. PMID: 11396361 Free article. Review.
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Capri G, Chang J, Chen SC, Conte P, Cwiertka K, Jerusalem G, Jiang Z, Johnston S, Kaufman B, Link J, Ro J, Schütte J, Oliva C, Parikh R, Preston A, Rosenlund J, Selzer M, Zembryki D, De Placido S. Capri G, et al. Among authors: conte p. Ann Oncol. 2010 Mar;21(3):474-480. doi: 10.1093/annonc/mdp373. Epub 2009 Oct 8. Ann Oncol. 2010. PMID: 19815649 Free article. Clinical Trial.
The sequential use of endocrine treatment for advanced breast cancer: where are we?
Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Buzdar A, Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C, Robertson JF. Barrios C, et al. Among authors: conte p. Ann Oncol. 2012 Jun;23(6):1378-86. doi: 10.1093/annonc/mdr593. Epub 2012 Feb 8. Ann Oncol. 2012. PMID: 22317766 Free PMC article. Review.
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry.
Bartsch R, Frings S, Marty M, Awada A, Berghoff AS, Conte P, Dickin S, Enzmann H, Gnant M, Hasmann M, Hendriks HR, Llombart A, Massacesi C, von Minckwitz G, Penault-Llorca F, Scaltriti M, Yarden Y, Zwierzina H, Zielinski CC; Biotherapy Development Association (BDA). Bartsch R, et al. Among authors: conte p. Ann Oncol. 2014 Apr;25(4):773-780. doi: 10.1093/annonc/mdt531. Epub 2013 Dec 18. Ann Oncol. 2014. PMID: 24351401 Free article.
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.
Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Dieci MV, et al. Among authors: conte p. Ann Oncol. 2014 Mar;25(3):611-618. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. Ann Oncol. 2014. PMID: 24401929 Free PMC article.
789 results